Magenta’s mission and culture are centered around the goal of enabling more patients with severe or life-threatening diseases to benefit from the potentially transformative potential of a curative stem cell transplant.
We believe we are the only company that is committed to addressing the major unmet needs in stem cell transplant and gene therapies. Magenta is focused on creating a comprehensive portfolio of therapies to optimize the blood and immune reset process in blood cancers, genetic diseases and autoimmune diseases.
At Magenta, we are applying our expertise in stem cell biology and drug discovery to bring innovative new therapies to the stem cell transplant field through our programs, specifically designed to address each of the key opportunities in the stem cell transplant journey for patients.
Our clinical and preclinical pipeline: